Carl Xiao

SVP of SPH HK Investment, Assistant GM of SPH-BIOCAD (HK) Limited

Carl holds an MBA & a Ph.D. degree of Genetics & Genomics from the University of Florida.

He has over 10 years of academic and industrial experience, especially in the antibody biologics drug development field.

He currently leads a 400-million USD joint venture project with a leading Russian biotech company called BIOCAD JSC which is involved in several commercial-stage oncology and immunology products.

He has participated in the evaluation of over 100+ early-stage projects, and managed to close an in-licensing deal for the Japanese drug, REMITCH, (treatment for renal dialysis and liver disease-related pruritus). Prior to Shanghai Pharma, he served in 3Sbio Inc. and Genor Biopharma Co., Ltd. as Senior Business Development Manager, Roche R&D Center Shanghai, as a scientist with the Roche pRED global team to conduct early-stage antibody drug development, the Radiology Department of Weil Cornell Medical College researching therapeutic antibody engineering.